EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Platelet-to-lymphocyte percentage ratio for assessing disease activity and predicting therapeutic outcomes in ulcerative colitis

Jieqi Zheng, Yu Wang, Li Li, Minhu Chen, Rirong Chen, Shenghong Zhang

International Immunopharmacology · 2024

DOI: 10.1016/j.intimp.2024.112506 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Jieqi Zheng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Blood Platelets. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIMS: Disease activity assessment and treatment outcome prediction are crucial in the patient management of ulcerative colitis (UC); yet the significance of platelet-to-lymphocyte percentage ratio (PLpR) remains unknown, which was investigated in this study. METHODS: We used data from three clinical trials: ACT 1, PURSUIT, and UNIFI. In total, 7,614 endoscopic procedures and 1,365 patients were included for assessing severity and predicting outcome, respectively. The primary outcome was endoscopic remission, defined as a Mayo endoscopic score of 0. The diagnostic capacity of PLpR was evaluated by the area under the receiver operating characteristic curve (AUC) while multivariable logistic regression was employed to assess the prognostic power of PLpR. RESULTS: PLpR showed higher AUCs than C-reactive protein in identifying endoscopic remission (P < 0.001) and improvement (P < 0.001). Besides, combining PLpR with fecal calprotectin enhanced the power to distinguish disease activity. In therapeutic outcome analyses, higher PLpR level indicated worse long-term outcomes. PLpR ≥ 1016.7 predicted a lower likelihood of endoscopic remission (OR: 0.50 [95 % CI: 0.39-0.65]; P < 0.001), endoscopic improvement (OR: 0.45 [95 % CI: 0.36-0.57]; P < 0.001), clinical remission (OR: 0.50 [95 % CI: 0.39-0.62]; P < 0.001), histologic improvement (OR: 0.50 [95 % CI: 0.31-0.79]; P = 0.004), and histologic-endoscopic mucosal improvement (OR: 0.42 [95 % CI: 0.27-0.66]; P < 0.001). Moreover, PLpR added the prognostic value to C-reactive protein, fecal calprotectin, clinical and endoscopic scores to predict long-term outcomes. CONCLUSION: PLpR could be a promising biomarker for monitoring disease activity and predicting long-term therapeutic outcomes in UC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeBlood PlateletsHumansMaleFemaleAdultMiddle AgedTreatment OutcomeLymphocytesPrognosisSeverity of Illness IndexFecesLeukocyte L1 Antigen ComplexRemission InductionPlatelet CountC-Reactive ProteinBiomarkers

Stichwörter der Autor:innen

BiomarkersDisease activityPlatelet-to-lymphocyte percentage ratioTherapeutic outcomeUlcerative colitis

Substanzen

Leukocyte L1 Antigen ComplexC-Reactive ProteinBiomarkers

Autor:innen und Institutionen

  • Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
  • Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. Electronic address: chenrr29@mail.sysu.edu.cn.
  • Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China; Guangxi Hospital Division of The First Affiliated Hospital, Sun Yat-sen University, Nanning, China. Electronic add…

Zitieren

APA

Zheng, J., Wang, Y., Li, L., Chen, M., Chen, R., & Zhang, S. (2024). Platelet-to-lymphocyte percentage ratio for assessing disease activity and predicting therapeutic outcomes in ulcerative colitis. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112506

Vancouver

Zheng J, Wang Y, Li L, Chen M, Chen R, Zhang S. Platelet-to-lymphocyte percentage ratio for assessing disease activity and predicting therapeutic outcomes in ulcerative colitis. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112506

BibTeX
@article{Zheng2024,
  author = {Zheng, Jieqi and Wang, Yu and Li, Li and Chen, Minhu and Chen, Rirong and Zhang, Shenghong},
  title = {Platelet-to-lymphocyte percentage ratio for assessing disease activity and predicting therapeutic outcomes in ulcerative colitis},
  journal = {International Immunopharmacology},
  year = {2024},
  doi = {10.1016/j.intimp.2024.112506}
}
Kostenlos starten →